Novartis AG (NYSE:NVS) Expected to Earn Q3 2025 Earnings of $1.98 Per Share

Novartis AG (NYSE:NVS) – Equities researchers at Zacks Research cut their Q3 2025 earnings estimates for Novartis in a report released on Monday, April 22nd. Zacks Research analyst E. Bagri now expects that the company will post earnings per share of $1.98 for the quarter, down from their previous forecast of $1.99. The consensus estimate for Novartis’ current full-year earnings is $7.15 per share.

Other equities research analysts also recently issued reports about the stock. Morgan Stanley started coverage on shares of Novartis in a research note on Tuesday, January 23rd. They set an “equal weight” rating and a $114.00 price objective for the company. BMO Capital Markets lifted their price objective on shares of Novartis from $114.00 to $116.00 and gave the stock a “market perform” rating in a research note on Wednesday. Three equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $115.00.

Novartis Trading Up 0.7 %

NYSE:NVS opened at $99.06 on Wednesday. Novartis has a 12 month low of $92.19 and a 12 month high of $108.78. The firm has a fifty day simple moving average of $97.92 and a 200-day simple moving average of $98.99. The company has a current ratio of 1.15, a quick ratio of 0.93 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $202.48 billion, a P/E ratio of 13.37, a PEG ratio of 1.58 and a beta of 0.54.

Novartis (NYSE:NVS) last announced its earnings results on Tuesday, January 30th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). Novartis had a net margin of 31.33% and a return on equity of 31.12%. The firm had revenue of $11.42 billion during the quarter, compared to analyst estimates of $11.69 billion. During the same quarter last year, the business earned $1.51 earnings per share.

Novartis Increases Dividend

The firm also recently announced an annual dividend, which was paid on Thursday, March 7th. Investors of record on Friday, March 8th were given a dividend of $3.7772 per share. The ex-dividend date of this dividend was Thursday, March 7th. This is an increase from Novartis’s previous annual dividend of $3.47. This represents a yield of 3.1%. Novartis’s payout ratio is currently 32.79%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Murphy Middleton Hinkle & Parker Inc. lifted its position in Novartis by 4.9% during the fourth quarter. Murphy Middleton Hinkle & Parker Inc. now owns 2,072 shares of the company’s stock valued at $209,000 after purchasing an additional 97 shares during the period. Pinnacle Bancorp Inc. increased its holdings in Novartis by 2.8% in the fourth quarter. Pinnacle Bancorp Inc. now owns 3,641 shares of the company’s stock valued at $368,000 after buying an additional 98 shares in the last quarter. Optimum Investment Advisors increased its holdings in Novartis by 23.3% in the fourth quarter. Optimum Investment Advisors now owns 530 shares of the company’s stock valued at $54,000 after buying an additional 100 shares in the last quarter. Chesley Taft & Associates LLC increased its holdings in Novartis by 0.3% in the fourth quarter. Chesley Taft & Associates LLC now owns 33,062 shares of the company’s stock valued at $3,338,000 after buying an additional 100 shares in the last quarter. Finally, Means Investment CO. Inc. increased its holdings in Novartis by 1.3% in the fourth quarter. Means Investment CO. Inc. now owns 8,074 shares of the company’s stock valued at $815,000 after buying an additional 103 shares in the last quarter. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.